Melanoma News and Research

Latest Melanoma News and Research

Online skin cancer detection training course improves physicians skill levels

Primary care physicians who took an online training course about skin cancer detection significantly improved their skill to properly diagnose and manage benign and malignant lesions, according to a national study from Henry Ford Hospital in Detroit.

8 Nov 2013

Majerus to donate $2M for new Primary Children's and Families' Cancer Research Center at HCI

Today the Majerus Family Foundation (a foundation Rick Majerus, former University of Utah basketball coach from 1989-2004, established prior to his death in 2012) announced that it will make a gift in the amount of $2 million toward the construction of the new Primary Children's and Families' Cancer Research Center at Huntsman Cancer Institute.

7 Nov 2013

Two long-term policyholders accuse Blue Cross of fraudulent scheme

Blue Cross was sued Monday in Los Angeles Superior Court in separate actions by two long-term policyholders who allege the health insurance giant induced them to switch from grandfathered policies in order to eventually cancel their health insurance.

6 Nov 2013

Scientists identify new algorithm to distinguish two subtypes of malignant melanoma

Scientists of the University of Ulm and Columbia University have discovered a diagnostic algorithm to distinguish two subtypes of malignant melanoma. Desmoplastic and spindle cell melanoma may look alike - they often resemble little scars or retractions of the skin - but differ in prognosis and therapeutic options.

4 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, announced that its most advanced ImmTAC drug, IMCgp100 for the treatment of late stage melanoma, has reached Maximum Tolerated Dose (MTD) and the dose escalation part of this Phase I clinical study has been completed. The company has now initiated a Phase IIa clinical trial in the UK and USA.

1 Nov 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Firstly, actinic keratosis (AK) is a common dermatological condition caused by cumulative exposure to the sun. Providing patients with effective treatment is very important, as AK can lead to forms of non-melanoma skin cancer (NMSC) if not diagnosed and treated early. In fact, two in three cases of squamous cell carcinoma (a common form of skin cancer), begin as AK.

29 Oct 2013

Dermatologists provide list of specific treatments, procedures not required for medical care

The American Academy of Dermatology today released its list of specific treatments and procedures related to skin health and care that are not always necessary.

29 Oct 2013

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Polaris Group announced today that positive results from a randomized Phase 2 trial of ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, for the treatment of malignant pleural mesothelioma were presented at the World Conference on Lung Cancer in Sydney, Australia.

28 Oct 2013

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

23 Oct 2013

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Aduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for CRS-207, a novel immunotherapy, for the treatment of pancreatic cancer.

22 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body.

19 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Women diagnosed with breast cancer are 39% more likely to develop second cancer

Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.

18 Oct 2013

Resveratrol can make tumor cells more susceptible to radiation treatment

A recent study by a University of Missouri researcher shows that resveratrol, a compound found in grape skins and red wine, can make certain tumor cells more susceptible to radiation treatment. This research, which studied melanoma cells, follows a previous MU study that found similar results in the treatment of prostate cancer.

12 Oct 2013

Melanoma News and Research

Latest Melanoma News and Research

Online skin cancer detection training course improves physicians skill levels

Majerus to donate $2M for new Primary Children's and Families' Cancer Research Center at HCI

Two long-term policyholders accuse Blue Cross of fraudulent scheme

Scientists identify new algorithm to distinguish two subtypes of malignant melanoma

Experimental drug effective in treating patients with non-small cell lung cancer

Immunocore’s Phase IIa clinical trial for IMCgp100 in melanoma initiates in the UK and USA

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Physician treatment perceptions in actinic keratosis: an interview with Kim Kjøller, Senior Vice President for Global Development, LEO Pharma

Dermatologists provide list of specific treatments, procedures not required for medical care

Polaris Group reports positive results from ADI-PEG 20 Phase 2 trial for malignant pleural mesothelioma

Functional biomarker could help guide treatment of patients with BRAF-mutant melanomas

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Women diagnosed with breast cancer are 39% more likely to develop second cancer

Resveratrol can make tumor cells more susceptible to radiation treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in